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Abstract This study aims to determine the prevalence of
methotrexate-induced nausea and vomiting in both adolescent
and adult patients with inflammatory arthritis. A survey of
methotrexate side effects was conducted on patients with
inflammatory arthritis. We provided a brief questionnaire to
unselected patients with inflammatory arthritis being treated
with methotrexate attending adolescent and adult rheumatol-
ogy clinics. The questions related to the presence, absence,
and severity of nausea and vomiting, the temporal relationship
with methotrexate and whether anti-emetics had been pre-
scribed. A total of 106 patients from the age of 13 years and
above—57 adults (over 20 years) and 49 adolescents (13–
19 years) were included in this study. The median age for
those experiencing nausea was 19 years (interquartile range
(IQR) 7) and for those with no nausea 55 years (IQR 46)
(p <0.001). Thirty-six out of 49 adolescent patients reported
nausea (73 %) compared to only 20/57 adults (35 %)
(p <0.001). Multiple logistic regression analysis showed that
the nausea group had a significantly higher proportion of
adolescents (p =0.0002), patients taking subcutaneous (SC)
methotrexate MTX (p =0.002), and patients with duration of
MTX of more than 1 year (p =0.049). Adolescents were
estimated to have over 6 times higher odds of nausea com-
pared to adults (OR 6.31, 95 % CI 2.38 to 16.75, p =0.0002)
after adjusting for SC MTX and duration of MTX. Only 22 %
of adolescents and 10 % of adults were prescribed anti-
emetics. There is a higher prevalence ofMTX-induced nausea
and vomiting in adolescents and younger adult patients with
inflammatory arthritis compared to older adults. The role of
anti-emetics in the treatment of these symptoms is unclear.










Nausea is one of themost frequent side effects of methotrexate
(MTX) [1] that may adversely impact on the adherence and
tolerability of this drug. These issues are especially important
in the care of adolescent patients, yet little is known regarding
the prevalence of these side effects in this age group, whether
it differs from adult patients, to what extent and what the risk
factors may be. We conducted a survey of adolescent and
adult patients with inflammatory arthritis being treated with
MTX to determine if MTX-induced nausea and vomiting was
present and if so, whether this was being adequately treated
with anti-emetics. Data was collected from a self-completed
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questionnaire of patients on methotrexate attending a single
unit’s clinic.
Methods
Patients with inflammatory arthritis, taking MTX, attending a
dedicated adolescent rheumatology clinic and an adult
rheumatology MTX monitoring clinic at University College
London Hospital (UCLH) over a 12-week period were includ-
ed in this study. Adolescence was defined as 10–19 years in
keeping with the WHO [2]. The adolescent unit at UCLH
cares for patients from age 12 years and above.
This survey was performed under good clinical practice
conditions. A MTX intolerance enquiry questionnaire was
constructed, consisting of two sections. The first section was
designed to explore the dose/duration of methotrexate, folic
acid supplementation, compliance with treatment, and side
effects experienced by the patient. In this section, patients
were requested to tick the side effects they were experiencing
from a list of all possible methotrexate-related side effects.
Only patients who ticked yes to nausea or vomiting were
asked to proceed with the second part of the questionnaire
which explored these symptoms in further details.
The second section obtained information regarding the
onset of these symptoms—whether prior to (anticipatory),
when thinking of (associative) or occurred after taking
MTX. On each item, a patient could score intensity as 0 (no
complaints), 1 (mild complaints), 2 (moderate complaints) or
3 (severe complaints). Duration of symptoms was scored as
lasting few hours, >1 day and all the time. Last question was
regarding the use of anti-emetics and its benefit.
For the purpose of this study, we included patients who
were using either oral or parenteral MTX as a single DMARD
therapy for at least 3 months. From the medical records,
information was confirmed on duration of MTX use, MTX
route of administration and MTX dose. A doctor or nurse
personally discussed the survey and handed over the ques-
tionnaire to all the patients who visited the rheumatology
clinic during the study period if they met above the criteria.
There was no help required from clinical staff to complete this
questionnaire as it only consisted of a set of simple tick box
style questions. Younger adolescents occasionally consulted
an accompanying adult to complete the questionnaire. All
patients returned the completed questionnaire back to the
clinical staff.
As this was a survey to determine incidence of nausea/
vomiting and anti-emetic prescribing in patients on MTX, no
ethical approval was required. All questions used to collect the
information were those used in routine clinical consultation as
part of the patient’s standard care. Nausea is difficult to
measure, being a subjective symptom, and its perception can
vary widely. It was therefore necessary to collect data with the
help of a set of appropriate questions prompting patients to
accurately report the occurrence and impact of nausea.
Statistical analysis
For categorical variables with more than two categories, a chi-
squared test-for-trend was used to compare between age
groups (adolescent or adult). Otherwise, analysis of categori-
cal variables involved using Fisher’s exact tests to compare
between groups. In particular, Fisher’s exact tests were used to
compare the incidence of nausea and vomiting between age
groups; and this analysis was supported by the presentation of
the 95 % confidence interval for the difference in percentages.
These 95 % confidence intervals were calculated using
Newcombe’s method [3]. A non-parametric Mann–Whitney
U test was used to compare patient age between those with
nausea versus those without; whereas an independent sample
t test was used to compare MTX dose between groups
because this was an approximately normally distributed
continuous variable.
A logistic regression method was used to investigate the
effect of several variables at once on the incidence of nausea
and vomiting. Forwards model selection (likelihood ratio
testing) was used in the context of logistic regression to
identify significant predictors of outcome among the variables
gender, MTX dose, subcutaneous (SC) MTX, duration, and
age group (adolescent or adult). Results were presented as
odds ratios (OR) with 95 % confidence intervals.
All analyses were computed using SPSS software version
18 [4], except R software [5] was used to calculate 95 %
confidence intervals for the difference in proportions and
Prism used to calculate Mann–WhitneyU . A 5% significance
level was used throughout.
Results
We surveyed a total of 106 patients—57 adults (68% females)
and 49 adolescents (71 % females). The median age of the
adults was 55 years (interquartile range (IQR) 28) and the
adolescents 18 years (IQR 2). Thirty-three percent of adults
were on SC MTX (19/57) compared to 49 % of adolescents
(24/49). Between the two age groups, there was no significant
difference in gender (p =0.83) or dose of MTX (p =0.12).
Combing all the patients, the median age for presence of
nauseawas 19 years (IQR7) and thosewith no nausea 55 years
(IQR 46) (p <0.001) [Fig. 1]. Thirty-six out of 49 adolescents
reported nausea (73 %) compared to only 20/57 adults (35 %)
(p <0.001). Twenty-one out of 49 adolescents experienced
vomiting (43 %) compared to only 6/57 adults (11 %) (p <
0.001). Interestingly, patients on parenteral MTX reported
higher prevalence of nausea compared to those on oral MTX
(77 versus 37 %, p <0.0001). Bivariate analyses (Table 1)
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showed that the nausea group had a significantly higher pro-
portion of adolescents (p <0.0001), females (p =0.019), pa-
tients taking SCMTX (p <0.0001), and patients with duration
of MTX of more than 1 year (p =0.04). The group in those
with vomiting also had a significantly higher proportion of
adolescents (p =0.0002). There was insufficient evidence that
MTX dosage is associated with either nausea or vomiting.
Separatemultiple logistic regression analyseswere performed
on the nausea and vomiting outcome variables, using forwards
model selection (likelihood ratio testing) to identify significant
predictors of outcome. Gender, MTX dose, SC MTX, duration
of MTX, and age group (adolescent or adult) were all made
available for inclusion in the logistic regression models. The
final model results for nausea are shown in Table 2.
Adolescent patients were estimated to have over 6 times
higher odds of nausea compared to adult patients (OR 6.31,
95 % CI 2.38 to 16.75, p =0.0002) after adjusting for SC
MTX and duration of MTX. SC MTX (OR 4.49, 95 % CI
1.71 to11.79, p =0.002) and duration ofMTX (OR 3.86, 95 %
CI 1.00 to 14.89, p =0.05) were also found to be significantly
associated with nausea. Although the bivariate analyses sug-
gested gender as a possible predictor of outcome, there was no
significant effect of gender on nausea after adjusting for age
group, SC MTX and duration. Only the age group was a
significant predictor of vomiting. Again, adolescent patients
were estimated to have over 6 times higher odds of vomiting
compared to adult patients (OR 6.38, 95 % CI 2.30 to 17.64;
p =0.0004).
In both groups, nearly all patients who reported nausea and
vomiting were experiencing these symptoms after methotrex-
ate intake. Fifty two percent (19) of adolescents and 30 % [6]
of adults had associative nausea. While none of the adult
patients experienced anticipatory or associative vomiting,
Fig. 1 Patients with inflammatory arthritis taking methotrexate attending
adolescent and adult rheumatology clinics. Median is shown for each and
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13 % of adolescents reported these symptoms. Forty one
percent (15) of adolescents and 30% [6] of adults experienced
anticipatory nausea.
Only 11 (22 %) adolescents and 6 (10 %) adults indicated
being on anti-emetics. Six adolescents (55 %) and five adults
(83 %) reported none or little benefit from anti-emetics. Only
one adult experienced “quite a lot” of benefit.
Discussion
To our knowledge, this is the first study to demonstrate a clear
inverse relationship between the presence of MTX-induced
nausea/vomiting and age in adolescent and adult patients. A
high prevalence of MTX-induced gastro-intestinal intolerance
in JIA has recently been reported by Bulatović et al. [6]. Our
questionnaire contained similar information as to the nausea
and vomiting domain of MTX intolerance severity score
questionnaire used by Bulatović et al.
We found a higher prevalence of nausea and vomiting not
only in adolescents but also in young adults showing a clear
inverse relationship between MTX-induced nausea and age.
As demonstrated in Table 1, there was insufficient evidence of
a relationship between nausea and dose of MTX, which was
unexpected. This is supported by a study by Lin et al. which
reported that there were no significant differences between
MTX concentrations above or below safety values and
nausea/vomiting in adult oncology patients on high-dose
methotrexate chemotherapy [7]. It is still unknown which
factors influence the MTX metabolic process, and the effects,
if any, of age and sex. In our study, the association of nausea in
patients on MTX for more than 1 year raises the possibility of
a cumulative effect of this drug on nausea.
Higher prevalence in patients on parenteral MTX may be
related to the frequent occurrence of anticipatory and associa-
tive complaints in adolescents. It suggests that classical con-
ditioning plays an important role in MTX intolerance in this
group [6, 8, 9]. However, it is interesting to note that Verkaaik
et al. did not find behavioural therapy and parenteral MTX
being more effective than the oral MTX with anti-emetics in
treating MTX intolerance [10]. Whilst the exact cause of this
complex issue in younger patients with inflammatory arthritis
is unknown, stimulation of chemoreceptor trigger zone has
been postulated. Therefore, treatment with 5-HT3 receptor
antagonist has been suggested by some authors [11, 12]. In
our study, very few patients were taking anti-emetics. It
would be interesting to study this further with a view of
finding out compliance with anti-emetics and reasons for
poor adherence.
Although our study has a moderate sample size for a study
of adolescent patients with arthritis, we accept that there may
have been low power to detect clinically relevant effects due
to the overall small sample size. Also, there are some limita-
tions given that this is a self-reported data. In particular,
respondent bias may have affected the results. Also, as a
service evaluation study rather than a research study, it might
not have captured all factors associated with MTX-induced
nausea and vomiting. For example, it would be relevant to
have also included body mass index in the multiple regression
analysis, however, this data was unavailable given that height
is not routinely measured in the adult clinic. We observed that
patients on parenteral MTX had a higher prevalence of
nausea/vomiting. It is possible that the same patients had these
symptoms whilst on oral MTX and hence, they were switched
to parenteral form. Findings presented here should be consid-
ered as exploratory rather than confirmatory. It is not possible
to identify causal relationships on the basis of a cross-sectional
study. It would also be of interest to investigate younger
adolescents and paediatric patients to ascertain if these find-
ings indeed peak with adolescence or are also as or more
prevalent in younger children.
In conclusion, we have found evidence of a higher preva-
lence of MTX-induced nausea and vomiting in adolescents
and younger adult patients with inflammatory arthritis com-
pared to older adults. In addition to younger age, these symp-
toms are associated with parenteral administration and longer
duration of MTX. The usefulness of anti-emetics in the treat-
ment is unclear. These findings support a more proactive
approach to counselling and managing MTX-induced nausea
in adolescent and young adult patients with inflammatory
arthritis. This may in part explain why adherence is often a
particular problem in younger patients. Further scientific study
is required to delineate why younger age associates with more
nausea.
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Table 2 Multiple logistic regression analysis: performed using forward
model selection with a 5 % significance level
Odds ratio 95 % CI p Value
Adolescent 6.312 2.379 to 16.746 0.0002
SC MTX 4.487 1.708 to 11.785 0.002
Duration of MTX more
than 1 year
3.865 1.003 to 14.889 0.049
The outcome is nausea (yes or no)
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